Compare BMRA & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMRA | SNOA |
|---|---|---|
| Founded | 1971 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 6.1M |
| IPO Year | 1995 | 2006 |
| Metric | BMRA | SNOA |
|---|---|---|
| Price | $2.33 | $1.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.0K | ★ 363.0K |
| Earning Date | 04-13-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,311,000.00 | ★ $14,288,000.00 |
| Revenue This Year | N/A | $23.00 |
| Revenue Next Year | N/A | $24.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 12.19 |
| 52 Week Low | $1.87 | $0.85 |
| 52 Week High | $4.60 | $6.92 |
| Indicator | BMRA | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 59.04 | 30.79 |
| Support Level | $2.12 | $0.85 |
| Resistance Level | $2.40 | $1.25 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 61.56 | 30.43 |
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.